"Dexmedetomidine for hyperactive delirium at the end of life: An open-l" by Benjamin Thomas, Wing Shan Angela Lo et al.
Abstract Background: Terminal delirium, specifically the hyperactive delirium subtype at the end of life, is common in palliative care patients. Standard care often involves sedation to alleviate distress. The alpha -adrenoreceptor agonist dexmedetomidine may have promise in terminal delirium, due to its properties of decreasing delirium and permitting rousable sedation. Aim: This study aimed to describe the effect of dexmedetomidine on delirium and sedation, when delivered via continuous subcu...
Memorial Delirium Assessment Scale Richmond Agitation Sedation Scale Palliative Version Conscious Sedation Ypnotics And Sedatives Pilot Projects
Source: uow.edu.au